title: CNS recurrence following CD34+ peripheral blood stem cell transplantation in stage 4 neuroblastoma.
abstract: We report here central nervous system (CNS) recurrence in neuroblastoma (NBL) after CD34(+) peripheral blood stem cell transplantation (PBSCT). Fifteen stage 4 NBL patients underwent CD34(+) transplantation with myeloablative chemotherapy consisting of carboplatin, etoposide, and melphalan. There were three primary site recurrences and five distant metastases including four brain metastases (two isolated CNS recurrences) at 4-7 months after CD34(+) transplantation. Three of four patients died of CNS progressive disease at 2, 8, and 9 months after recurrence and the remaining single patient was lost to follow-up. CNS recurrence in NBL is fatal and requires identification of risk factors and more effective treatment strategies.
authors.affiliation: Department of Pediatrics and Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea.
authors.forename: Hyoung Soo
authors.initials: HS
authors.lastname: Choi
authors.forename: Sang Hyeok
authors.initials: SH
authors.lastname: Koh
authors.forename: Eun Sil
authors.initials: ES
authors.lastname: Park
authors.forename: Hee Young
authors.initials: HY
authors.lastname: Shin
authors.forename: Hyo Seop
authors.initials: HS
authors.lastname: Ahn
mesh_terms: D018952:Antigens, CD34; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000556:secondary*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D007723:Korea / Q000453:epidemiology; D008297:Male; D009447:Neuroblastoma / Q000453:epidemiology / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D012306:Risk
chemical_list: D018952:Antigens, CD34